1
|
Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Eur J Cancer 2019; 114:128-136. [PMID: 31060925 DOI: 10.1016/j.ejca.2019.03.025] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Accepted: 03/28/2019] [Indexed: 11/28/2022]
Abstract
Academic, industry, regulatory leaders and patient advocates in cancer clinical research met in November 2018 at the Innovation and Biomarkers in Cancer Drug Development meeting in Brussels to address the existing dichotomy between increasing calls for personalised oncology approaches based on individual molecular profiles and the need to make resource and regulatory decisions at the societal level in differing health-care delivery systems around the globe. Novel clinical trial designs, the utility and limitations of real-world evidence (RWE) and emerging technologies for profiling patient tumours and tumour-derived DNA in plasma were discussed. While randomised clinical trials remain the gold standard approach to defining clinical utility of local and systemic therapeutic interventions, the broader adoption of comprehensive tumour profiling and novel trial designs coupled with RWE may allow patient and physician autonomy to be appropriately balanced with broader assessments of safety and overall societal benefit.
Collapse
Affiliation(s)
- Roberto Salgado
- Department of Pathology GZA-ZNA, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Australia.
| | - David B Solit
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - David L Rimm
- Dept. of Pathology, Yale University School of Medicine, New Haven, CT, USA; Dept. of Medicine, Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | | | - Paul N Span
- Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | | | - Amr Makady
- The National Healthcare Institute (ZIN), Diemen, the Netherlands
| | - L Bergmann
- Medical Clinic II, University Hospital Frankfurt, Germany; Ambulantes Krebszentrum Frankfurt, Germany
| | - Sumimasa Nagai
- Translational Research Center, The University of Tokyo Hospital and PMDA, Tokyo, Japan
| | - Chris Smith
- CRUK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
| | - Mark Robson
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Emile Voest
- The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | | | - Philippe Lambin
- The D-Lab & The M-Lab, Department of Precision Medicine, GROW Research Institute for Oncology, Maastricht, The Netherlands
| | | | | | | | | | | |
Collapse
|
2
|
Lyerly HK, Ren J, Canetta R, Kim GH, Nagai S, Yamaguchi T, Hatogai K, Katayama H, Da Rocha Dias S, McManus D, Soltys K, Yang Z, Olopade O, Goodman N, Reaman G, Gross T. Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers. J Glob Oncol 2019; 4:1-11. [PMID: 30521412 PMCID: PMC7010455 DOI: 10.1200/jgo.18.00092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Advances in genetic sequencing and other diagnostic technologies have enabled the use of precision medicine in clinical cancer care, as well as the development of novel therapies that are targeted to specific molecular drivers of cancer. Developing these new agents and making them accessible to patients requires global clinical studies and regulatory review and approval by different national regulatory agencies. Whereas these global trials present challenges for drug developers who conduct them and regulatory agencies who oversee them, they also raise practical issues about patients with low-frequency cancers who need these therapies. A lack of uniform standards in both regulatory approval for marketing and reimbursement for approved agents across countries may make the newly developed agent either unavailable or inaccessible to patients in certain countries or regions, even if patients from those countries or regions participated in the clinical research that established the safety and efficacy of the agent. In an effort to further understand and address this need, we convened an international workshop in 2017 in North Bethesda, MD. After presentations of the individual regulatory pathways for marketing approval and reimbursement for individual nations, participants discussed expedited pathways and specific challenges for uncommon cancers. As a matter of justice, agents being developed for rare cancers, pediatric cancers, or uncommon molecular subsets of common cancers need a pragmatic, science-based regulatory policy framework to clearly specify the type and quantity of evidence needed to demonstrate efficacy from these trials and evidence to support accessibility.
Collapse
Affiliation(s)
- H Kim Lyerly
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Jun Ren
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Renzo Canetta
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Gi Hyun Kim
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Sumimasa Nagai
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Tomohiro Yamaguchi
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Ken Hatogai
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Hiroshi Katayama
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Silvy Da Rocha Dias
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Daniel McManus
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Kathy Soltys
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Zhimin Yang
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Olufumilayo Olopade
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Nancy Goodman
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Greg Reaman
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| | - Thomas Gross
- H. Kim Lyerly, Duke University, Durham, NC; Jun Ren, Capital University Medical Center; Zhimin Yang, China Food and Drug Administration, Beijing, People's Republic of China; Gi Hyun Kim, Korea Ministry of Food and Drug Safety, Seoul, South Korea; Sumimasa Nagai, University of Tokyo; Sumimasa Nagai, Tomohiro Yamaguchi, and Ken Hatogai, Pharmaceuticals and Medical Devices Agency; Hiroshi Katayama, National Cancer Center Hospital, Tokyo, Japan; Silvy Da Rocha Dias, European Medicines Agency, London, United Kingdom; Daniel McManus and Kathy Soltys, Health Canada, Ottawa, Ontario, Canada; Olufumilayo Olopade, University of Chicago, Chicago, IL; Nancy Goodman, Kids V Cancer, Washington, DC; Greg Reaman, US Food and Drug Administration; Thomas Gross, US National Cancer Institute, Bethesda, MD, and Renzo Canetta, Independent Consultant
| |
Collapse
|
3
|
Berman D, Korman A, Peck R, Feltquate D, Lonberg N, Canetta R. The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience. Pharmacol Ther 2014; 148:132-53. [PMID: 25476108 DOI: 10.1016/j.pharmthera.2014.11.017] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Accepted: 11/24/2014] [Indexed: 12/19/2022]
Abstract
The discovery and increased understanding of the complex interactions regulating the immune system have contributed to the pharmacologic activation of antitumor immunity. The activity of effector cells, such as T and NK cells, is regulated by an array of activating and attenuating receptors and ligands. Agents that target these molecules can modulate immune responses by exerting antagonistic or agonistic effects. Several T- or NK-cell modulators have entered clinical trials, and two have been approved for use. Ipilimumab (Yervoy®, Bristol-Myers Squibb) and nivolumab (OPDIVO, Ono Pharmaceutical Co., Ltd./Bristol-Myers Squibb) were approved for the treatment of metastatic melanoma, in March 2011 in the United States, and in July 2014 in Japan, respectively. The clinical activity of these two antibodies has not been limited to tumor types considered sensitive to immunotherapy, and promising activity has been reported in other solid and hematologic tumors. Clinical development of ipilimumab and nivolumab has presented unique challenges in terms of safety and efficacy, requiring the establishment of new evaluation criteria for adverse events and antitumor effects. Guidelines intended to help oncologists properly manage treatment in view of these non-traditional features have been implemented. The introduction of this new modality of cancer treatment, which is meant to integrate with or replace the current standards of care, requires additional efforts in terms of optimization of treatment administration, identification of biomarkers and application of new clinical trial designs. The availability of immune modulators with different mechanisms of action offers the opportunity to establish immunological combinations as new standards of care.
Collapse
Affiliation(s)
- David Berman
- Bristol-Myers Squibb, Research and Development Division, United States
| | - Alan Korman
- Bristol-Myers Squibb, Research and Development Division, United States
| | - Ronald Peck
- Bristol-Myers Squibb, Research and Development Division, United States
| | - David Feltquate
- Bristol-Myers Squibb, Research and Development Division, United States
| | - Nils Lonberg
- Bristol-Myers Squibb, Research and Development Division, United States
| | - Renzo Canetta
- Bristol-Myers Squibb, Research and Development Division, United States.
| |
Collapse
|
4
|
Bertagnolli MM, Canetta R, Nass SJ. Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century". Oncologist 2014; 19:1179-85. [PMID: 25326161 PMCID: PMC4221375 DOI: 10.1634/theoncologist.2014-0240] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2014] [Accepted: 09/10/2014] [Indexed: 11/17/2022] Open
Abstract
Since their inception in the 1950s, the National Cancer Institute-funded cancer cooperative groups have been important contributors to cancer clinical and translational research. In 2010, a committee appointed by the Institute of Medicine (IOM) of the National Academy of Sciences completed a consensus review on the status of the U.S. publicly funded cancer clinical trials system. This report identified a need to reinvigorate the cooperative groups and provided recommendations for improving their effectiveness. Follow-up workshops to monitor progress were conducted by the IOM's National Cancer Policy Forum and the American Society of Clinical Oncology (ASCO) in 2011 and 2013. One of the key recommendations of the IOM report was a call for greater collaboration among stakeholders in cancer research. In particular, more active engagement and better alignment of incentives among the cooperative groups, the National Cancer Institute, the U.S. Food and Drug Administration, and the biopharmaceutical industry were identified as essential to achieving the promise of oncology drug development. This review, based on presentations and discussion during the IOM-ASCO workshops, outlines the progress and remaining challenges of these collaborations.
Collapse
Affiliation(s)
- Monica M Bertagnolli
- Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Bristol-Myers Squibb, Wallingford, Connecticut, USA; National Cancer Policy Forum, Institute of Medicine of the National Academies, Washington, D.C., USA
| | - Renzo Canetta
- Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Bristol-Myers Squibb, Wallingford, Connecticut, USA; National Cancer Policy Forum, Institute of Medicine of the National Academies, Washington, D.C., USA
| | - Sharyl J Nass
- Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Bristol-Myers Squibb, Wallingford, Connecticut, USA; National Cancer Policy Forum, Institute of Medicine of the National Academies, Washington, D.C., USA
| |
Collapse
|
5
|
Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R. An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology. Clin Trials 2013; 10:754-60. [PMID: 23935162 DOI: 10.1177/1740774513493973] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Measurement error in time-to-event end points complicates interpretation of treatment effects in clinical trials. Non-differential measurement error is unlikely to produce large bias [1]. When error depends on treatment arm, bias is of greater concern. Blinded-independent central review (BICR) of all images from a trial is commonly undertaken to mitigate differential measurement-error bias that may be present in hazard ratios (HRs) based on local evaluations. Similar BICR and local evaluation HRs may provide reassurance about the treatment effect, but BICR adds considerable time and expense to trials. METHODS We describe a BICR audit strategy [2] and apply it to five randomized controlled trials to evaluate its use and to provide practical guidelines. The strategy requires BICR on a subset of study subjects, rather than a complete-case BICR, and makes use of an auxiliary-variable estimator. RESULTS When the effect size is relatively large, the method provides a substantial reduction in the size of the BICRs. In a trial with 722 participants and a HR of 0.48, an average audit of 28% of the data was needed and always confirmed the treatment effect as assessed by local evaluations. More moderate effect sizes and/or smaller trial sizes required larger proportions of audited images, ranging from 57% to 100% for HRs ranging from 0.55 to 0.77 and sample sizes between 209 and 737. LIMITATIONS The method is developed for a simple random sample of study subjects. In studies with low event rates, more efficient estimation may result from sampling individuals with events at a higher rate. CONCLUSION The proposed strategy can greatly decrease the costs and time associated with BICR, by reducing the number of images undergoing review. The savings will depend on the underlying treatment effect and trial size, with larger treatment effects and larger trials requiring smaller proportions of audited data.
Collapse
Affiliation(s)
- Lori E Dodd
- aBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
LoRusso PM, Canetta R, Wagner JA, Balogh EP, Nass SJ, Boerner SA, Hohneker J. Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. Clin Cancer Res 2012; 18:6101-9. [PMID: 23065428 DOI: 10.1158/1078-0432.ccr-12-2455] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cancer cells contain multiple genetic changes in cell signaling pathways that drive abnormal cell survival, proliferation, invasion, and metastasis. Unfortunately, patients treated with single agents inhibiting only one of these pathways--even if showing an initial response--often develop resistance with subsequent relapse or progression of their cancer, typically via the activation of an alternative uninhibited pathway. Combination therapies offer the potential for inhibiting multiple targets and pathways simultaneously to more effectively kill cancer cells and prevent or delay the emergence of drug resistance. However, there are many unique challenges to developing combination therapies, including devising and applying appropriate preclinical tests and clinical trial designs, prioritizing which combination therapies to test, avoiding overlapping toxicity of multiple agents, and overcoming legal, cultural, and regulatory barriers that impede collaboration among multiple companies, organizations, and/or institutions. More effective strategies to efficiently develop combination cancer therapies are urgently needed. Thus, the Institute of Medicine's National Cancer Policy Forum recently convened a workshop with the goal of identifying barriers that may be impeding the development of combination investigational cancer therapies, as well as potential solutions to overcome those barriers, improve collaboration, and ultimately accelerate the development of promising combinations of investigational cancer therapies.
Collapse
Affiliation(s)
- Patricia M LoRusso
- Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA.
| | | | | | | | | | | | | |
Collapse
|
7
|
Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy. Semin Oncol 2010; 37:533-46. [DOI: 10.1053/j.seminoncol.2010.09.015] [Citation(s) in RCA: 181] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
8
|
Abstract
Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal tissues. A large number of new therapies are being evaluated in patients with sarcomas, and consensus criteria defining treatment responses are essential for comparison of results from studies completed by different research groups. The 1979 World Health Organization (WHO) handbook set forth operationally defined criteria for response evaluation in solid tumors that were updated in 2000 with the publication of the Response Evaluation Criteria in Solid Tumors (RECIST). There have been significant advances in tumor imaging, however, that are not reflected in the RECIST. For example, computed tomography (CT) slice thickness has been reduced from 10 mm to < or =2.5 mm, allowing for more reproducible and accurate measurement of smaller lesions. Combination of imaging techniques, such as positron emission tomography with fluorine-18-fluorodeoxyglucose (18FDG-PET) and CT can provide investigators and clinicians with both anatomical and functional information regarding tumors, and there is now a large body of evidence demonstrating the effectiveness of PET/CT and other newer imaging methods for the detection and staging of tumors as well as early determination of responses to therapy. The application of newer imaging methods has the potential to decrease both the sample sizes required for, and duration of, clinical trials by providing an early indication of therapeutic response that is well correlated with clinical outcomes, such as time to tumor progression or overall survival. The results summarized in this review support the conclusion that the RECIST and the WHO criteria for evaluation of response in solid tumors need to be modernized. In addition, there is a current need for prospective trials to compare new response criteria with established endpoints and to validate imaging-based response rates as surrogate endpoints for clinical trials of new agents for sarcoma and other solid tumors.
Collapse
Affiliation(s)
- Scott M Schuetze
- Department of Internal Medicine, Division of Hematology/Oncology, 1500 E. Medical Center Drive, C409 MIB, Ann Arbor, Michigan 48109-5843, USA. scotschu@umich
| | | | | | | |
Collapse
|
9
|
Abstract
OBJECTIVE BMS 310705 is a novel water-soluble analog of epothilone B currently in phase I clinical evaluation in the treatment of malignancies such as ovarian, renal, bladder, and lung carcinoma. Using an early passage cell culture model derived from the ascites of a patient clinically refractory to platinum/paclitaxel therapy, we evaluated the pathway of caspase-mediated apoptosis. METHODS Cells were treated for 1 h and subsequently evaluated for apoptosis, survival, and caspase activity. Apoptosis was determined by fluorescent microscopy. Caspase-3, -8, and -9 activities were determined by fluorometry using target tetrapeptide substrates. Mitochondrial release of cytochrome c was determined by immunoblot analysis. RESULTS After treatment with BMS 310705, apoptosis was confirmed in >25% of cells at 24 h. Survival was significantly lower (P < 0.02) in cells treated with 0.05 micro M BMS 310705 vs paclitaxel. Analysis revealed an increase of caspase-9 and -3 activity; no caspase -8 activity was observed. Release of cytochrome c was detected at 12 h following treatment. SN-38 and topotecan failed to induce apoptosis. CONCLUSIONS BMS 310705 induces significant apoptosis, decreases survival, and utilizes the mitochondrial-mediated pathway for apoptosis in this model.
Collapse
Affiliation(s)
- Denise Uyar
- The Cleveland Clinic Foundation, Experimental Therapeutics Program, Taussig Cancer Center/R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Canetta R. Nuove Frontiere Di Trattamento in Oncologia. Tumori 2000; 86:S13-4. [PMID: 11225406 DOI: 10.1177/03008916000866s105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- R Canetta
- Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, USA
| |
Collapse
|
11
|
Lebwohl DE, Canetta R. New developments in chemotherapy of advanced breast cancer. Ann Oncol 2000; 10 Suppl 6:139-46. [PMID: 10676565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
Anthracyclines and taxanes are the two most active classes of chemotherapy for the treatment of advanced breast cancer. Recent studies have investigated combination therapy including doxorubicin (Dox) and paclitaxel. The efficacy of this combination has been established in a phase III study conducted by ECOG, comparing Dox/paclitaxel versus Dox versus paclitaxel. The combination is superior to Dox or paclitaxel with respect to response rate and time to disease progression, indicating that the combination provides a new standard for the first line treatment of metastatic breast cancer [1]. Phase II studies using higher doses of Dox and using shorter infusions of paclitaxel have suggested the combination can be further optimized; Gianni reported a 94% objective response rate using Dox 60 mg/m2 followed by paclitaxel 175 mg/m2 given over three hours [2]. The more active regimens are associated with enhanced cardiotoxicity; this toxicity can be avoided, however, by limiting the exposure to doxorubicin. The newer regimens have now been moved into phase III studies. Future progress for this disease will depend on the introduction of new agents. Two novel drugs are currently being investigated in randomised phase III trials as potentiators of Dox and/or paclitaxel. One is a monoclonal antibody from Genentech (Herceptin, trastuzumab) directed at the HER-2/neu oncogene, which is overexpressed in > 25% of breast cancers [3]. Recent results indicate that Herceptin in combination with paclitaxel (or with a Dox plus cyclophosphamide regimen) induces a higher response rate (RR) and prolongs the time to disease progression when compared to chemotherapy alone. The second agent N,N-diethyl-2[4-(phenylmethyl)-phenoxy] ethanamine.HCl (DPPE, BMS-217380-01), when combined with Dox, was associated with a higher RR than previously observed with Dox alone [4]. A randomized trial of Dox versus Dox plus DPPE is ongoing. The possible mechanisms underlying chemo-potentiation by these agents are discussed. As new anthracycline/taxane combinations establish themselves in earlier stages of the disease, the need for effective, non-cross resistant salvage regimens will emerge.
Collapse
Affiliation(s)
- D E Lebwohl
- Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, USA
| | | |
Collapse
|
12
|
Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17:2355-64. [PMID: 10561297 DOI: 10.1200/jco.1999.17.8.2355] [Citation(s) in RCA: 166] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the place of single-agent paclitaxel compared with nonanthracycline combination chemotherapy as front-line therapy in metastatic breast cancer. PATIENTS AND METHODS Patients with previously untreated metastatic breast cancer were randomized to receive either paclitaxel 200 mg/m(2) intravenously (IV) over 3 hours for eight cycles (24 weeks) or standard cyclophosphamide 100 mg/m(2)/d orally on days 1 to 14, methotrexate 40 mg/m(2) IV on days 1 and 8, fluorouracil 600 mg/m(2) IV on days 1 and 8, and prednisone 40 mg/m(2)/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin recommended as second-line therapy. RESULTS A total of 209 eligible patients were randomized with a median survival duration of 17.3 months for paclitaxel and 13.9 months for CMFP. Multivariate analysis showed that patients who received paclitaxel survived significantly longer than those who received CMFP (P =.025). Paclitaxel produced significantly less severe leukopenia, thrombocytopenia, mucositis, documented infections (all P <.001), nausea or vomiting (P =.003), and fever without documented infection (P =.007), and less hospitalization for febrile neutropenia than did CMFP (P =.001). Alopecia, peripheral neuropathy, and myalgia or arthralgia were more severe with paclitaxel (all P <.0001). Overall, quality of life was similar for both treatments (P > = .07). CONCLUSION Initial paclitaxel was associated with significantly less myelosuppression and fewer infections, with longer survival and similar quality of life and control of metastatic breast cancer compared with CMFP.
Collapse
Affiliation(s)
- J F Bishop
- Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia. Taxol Investigational Trials Group
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
The positive impact on survival of traditional chemotherapeutic agents has renewed interest in developing newer cytotoxic agents and orally active compounds with improved therapeutic indices. In addition, new insights into the pathways of human tumorigenesis have led to novel approaches aimed at specific mechanism-based targets. The taxane class, of which paclitaxel was the first member, has the unique ability to promote and stabilize microtubule function directly, thereby inhibiting mitotic progression and inducing apoptotic cell death. Paclitaxel provides treatment benefit in a broad range of solid tumors including breast, ovarian, and lung cancer. The success with paclitaxel stimulated interest in the microtubule as a new therapeutic target. Taxane analogues with improved preclinical efficacy have been identified and are entering clinical trials. The enthusiasm for oral anticancer agents and the therapeutic importance of platinum compounds has led to the development of JM216 (satraplatin), a novel platinum IV coordination complex with oral activity in cisplatin-resistant cell lines, which is now in phase III trials in prostate cancer. Another compound in late development is DPPE, a chemopotentiator that enhances the in vivo antitumor effects of cytotoxic agents such as doxorubicin, cyclophosphamide, and cisplatin. Agents that inhibit topoisomerase I and II have also been of interest. TAS-103 is a dual topoisomerase I and II inhibitor with preclinical efficacy in a broad spectrum of tumors and in multidrug-resistant tumor cell lines. Vaccination strategies represent a rational therapeutic approach in the minimal residual disease or high-risk adjuvant therapy setting. The GMK and MGV vaccines utilizing ganglioside antigens overexpressed on human tumors such as melanoma and small cell lung cancer appear to induce antibody production reliably at tolerable doses and are under further clinical investigation. Inhibition of matrix metalloproteinases (MMPs) is another attractive target for intervention in several aspects of tumor progression. Local production of MMPs with subsequent degradation of the extracellular matrix is implicated in supporting tumor growth, invasion, and angiogenesis. The development of orally active, nontoxic MMP inhibitors is critical since these compounds will likely require chronic administration in conjunction with other therapies. Oncogenes and tumor suppressor genes are appealing targets for therapy since they are thought to be responsible for a significant number of cancers. Mutations in the Ras oncogene occur with great frequency in a number of human cancers including lung, pancreas, and colon cancer. Clinical development of potent and selective inhibitors of farnesyltransferase, the Ras-processing enzyme, is ongoing. These compounds uncouple Ras activity, affect tumor growth, and have demonstrated significant antitumor activity against experimental models of human cancer. The exciting compounds and novel therapeutic approaches currently under investigation by Bristol-Myers Squibb Pharmaceutical Research Institute offer great potential as effective cancer chemotherapy agents for the near future.
Collapse
Affiliation(s)
- K Ferrante
- Bristol-Myers Squibb Pharmaceutical Research Institute, Richard L. Gelb Center for Pharmaceutical Research and Development, Wallingford, CT 06492-7660, USA.
| | | | | |
Collapse
|
14
|
Kudelka AP, Verschraegen CF, Shen Y, Gonzalez De Leon C, Edwards CL, Freedman RS, Forman A, Gibbs HR, Mante R, Hord M, Canetta R, Krakoff I, Kavanagh JJ. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. Int J Gynecol Cancer 1999; 9:44-53. [PMID: 11240742 DOI: 10.1046/j.1525-1438.1999.09856.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The purpose of this study was to analyze the efficacy and toxicity of a high dose of paclitaxel in patients with ovarian cancer refractory to platinum chemotherapy. Another phase II study of hydroxyurea was run in the same patient population. Fifty patients with measurable ovarian cancer were entered on this phase II study at The University of Texas M. D. Anderson Cancer Center. Treatment consisted of 250 mg/m2 of paclitaxel given by continuous intravenous infusion over 24 h every 3 weeks. Patients with disease unresponsive to paclitaxel could then be crossed over to hydroxyurea, and vice versa. Twenty-five (53%) out of 47 evaluable patients had a response (two complete responses and 23 partial responses). Twelve (26%) patients had stable disease. The median survival was 11.3 months. The main toxic effect was neutropenia (98% of patients) with 28 (9%) episodes of neutropenic fever. Neutropenia required therapy with granulocyte colony-stimulating factor. Other side effects were alopecia (100%), anemia (98%), gastrointestinal problems (57%), stomatitis (27%), and neurotoxicity (55%). Paclitaxel administered at a high dose as a single agent proved to be very active in patients who had platinum-refractory ovarian cancer and was well tolerated. Further studies of high-dose paclitaxel in patients with ovarian carcinoma are indicated.
Collapse
Affiliation(s)
- A. P. Kudelka
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA; Bristol Myers Squibb, Wallingford, Connecticut, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D, Yeap BY. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998; 78:1479-87. [PMID: 9836481 PMCID: PMC2063202 DOI: 10.1038/bjc.1998.710] [Citation(s) in RCA: 180] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.
Collapse
|
17
|
Abstract
The vast amount of basic research on platinum coordination complexes has produced, over the past 25 years, several thousand new molecules for preclinical screening and 28 compounds which have entered clinical development. The goals of these research activities have been to identify compounds with superior efficacy, reduced toxicity, lack of cross-resistance or improved pharmacological characteristics as compared with the parent compound, cisplatin. After the remarkable therapeutic effects of cisplatin had been established, only a few other platinum compounds succeeded in reaching general availability. Whereas carboplatin is an analogue with an improved therapeutic index (mostly driven by reduced organ toxicity) over that of cisplatin, new compounds clearly more active than or non-cross-resistant with cisplatin have not yet been identified. The platinum analogues that remain under investigation are focusing on expanding the utilisation of platinum therapy to tumour types not usually treated with, or responsive to, cisplatin or carboplatin. In addition, novel routes of administration constitute another avenue of research. The clinical development of platinum coordination complexes, with emphasis on those compounds still under active development, is reviewed.
Collapse
Affiliation(s)
- D Lebwohl
- Bristol-Myers Squibb, Pharmaceutical Research Institute, Department 202, Wallingford, Connecticut 06492, USA
| | | |
Collapse
|
18
|
Hoff PM, Pazdur R, Benner SE, Canetta R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998; 9:479-90. [PMID: 9877235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
UFT is an oral antineoplastic drug combining uracil and tegafur in a 4:1 molar ratio. Tegafur acts as a prodrug of 5-fluorouracil (5-FU), being slowly metabolized by cytochrome P450 to 5-FU. Uracil competitively inhibits the metabolism of 5-FU, resulting in increased plasma and tumor 5-FU concentrations. At equimolar doses, higher peak plasma 5-FU concentrations are achieved with UFT plus oral leucovorin with similar systemic 5-FU exposure compared with low-dose continuous 5-FU infusions. The elimination half-life of 5-FU following UFT administration is approximately 7 h compared with 0.2 h with i.v. 5-FU. In phase II studies of UFT plus oral leucovorin for the treatment of advanced colorectal cancer, response rates ranged from 25 to 42%. UFT plus oral leucovorin is well tolerated, with manageable diarrhea being the only dose-limiting toxicity; the regimen is not associated with significant myelosuppression, mucositis, hand-foot syndrome or alopecia. UFT, with or without leucovorin, has also been evaluated alone or in combination with other cytotoxic agents for the treatment of advanced lung, breast and gastric cancers. UFT has also been evaluated as adjuvant therapy for colorectal, breast, gastric, head and neck, and superficial bladder cancers. UFT plus leucovorin offers patients an entirely oral cancer treatment, and appears to provide potential advantages over bolus 5-FU regimens with regard to toxicity and convenience of administration. These benefits should be advantageous in the adjuvant setting, as well as in advanced disease settings in which palliation is an important consideration. Ongoing clinical trials will further define the role of this promising oral treatment regimen.
Collapse
Affiliation(s)
- P M Hoff
- Department of Gastrointestinal Oncology and Digestive Diseases, University of Texas MD Anderson Cancer Center, Houston 77030, USA
| | | | | | | |
Collapse
|
19
|
Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Hellmann S, Canetta R, Friedman MA. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995; 13:2056-65. [PMID: 7543562 DOI: 10.1200/jco.1995.13.8.2056] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
PURPOSE To provide paclitaxel, an investigational drug at the inception of this study, to women with chemotherapy-refractory metastatic breast cancer and to evaluate response and toxicity in these patients. PATIENTS AND METHODS Two hundred sixty-seven patients with progressive disease (PD) following at least two chemotherapy regimens for metastatic breast cancer and a contraindication to further doxorubicin treatment received paclitaxel either at 175 mg/m2 intravenously (IV) over 24 hours or at 135 mg/m2 if they had prior irradiation to 30% of marrow-bearing bone or a cumulative dose of mitomycin > or = 20 mg/m2. RESULTS In a subgroup of patients (n = 172) with measurable disease, four complete responses (CRs) and 36 partial responses (PRs) occurred, for an overall response rate of 23% (95% confidence interval [CI], 17% to 30%). No differences in response rates were noted according either to the number of prior chemotherapy regimens received or to whether patients were considered refractory to doxorubicin. The dose and schedule used in this trial resulted in febrile neutropenia in 45% of patients and a hospitalization rate of 49%. CONCLUSION Paclitaxel's activity in this multiinstitutional trial in heavily pretreated patients confirms the encouraging results attained in single-institution trials. Although at this dose and schedule paclitaxel may be considered too myelosuppressive for palliative care, supportive measures such as colony-stimulating factors and antibiotics were not used prophylactically. Current research efforts are focusing on whether paclitaxel's activity against breast cancer is dose- and/or schedule-dependent, and on what role it has in patients with less advanced disease.
Collapse
Affiliation(s)
- J S Abrams
- Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892-7436, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11:2405-10. [PMID: 7902426 DOI: 10.1200/jco.1993.11.12.2405] [Citation(s) in RCA: 205] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
PURPOSE To provide an investigational drug, paclitaxel, now commercially available, to women with refractory ovarian cancer and to evaluate response and toxicity in these patients. PATIENTS AND METHODS Patients with platinum-refractory ovarian cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3, at least three prior chemotherapy regimens, adequate hepatic and renal function, and no significant cardiac history were eligible. Patients were treated with paclitaxel 135 mg/m2 administered by 24-hour continuous intravenous infusion every 3 weeks. RESULTS Leukopenia was the most frequent toxicity, with 78% of patients experiencing grade 3 or 4 toxicity. Other grade 3 and 4 toxicities were less common: fever (33%), infection (12%), thrombocytopenia (8%), vomiting (7%), cardiac (2%), neurologic (2%), and mucositis (1%). Fifteen treatment-related deaths (1.5%) were reported. The objective response rate was 22% (4% complete response [CR], 18% partial response; 95% confidence interval [CI] for overall response, 19% to 25%). The median time to progression from treatment initiation was 7.1 months in responding patients and 4.5 months for all patients. The median survival duration was 8.8 months. CONCLUSION Paclitaxel has shown activity in women with platinum-refractory ovarian cancer, and it can be administered with an acceptable safety profile. Further research is needed to determine the optimal role of paclitaxel in the primary and salvage treatment of ovarian cancer.
Collapse
Affiliation(s)
- E L Trimble
- Clinical Investigation Branch, National Cancer Institute, Rockville, MD 20852
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Arbuck SG, Canetta R, Onetto N, Christian MC. Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 1993; 20:31-9. [PMID: 8102016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Basic questions regarding optimal dose and schedule of anticancer drug administration frequently persist long after regulatory approval and commercial availability of a drug. For paclitaxel (TAXOL), these questions were considered early in drug development. This paper reviews the available preclinical studies that assessed different drug concentrations and durations of drug exposure. The current status of clinical trials designed to help resolve these issues is also reviewed.
Collapse
Affiliation(s)
- S G Arbuck
- Developmental Chemotherapy Section, National Cancer Institute, Bethesda, MD 20892
| | | | | | | |
Collapse
|
22
|
Allan JD, Connolly KJ, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. Clin Infect Dis 1993; 16 Suppl 1:S46-51. [PMID: 8425019 DOI: 10.1093/clinids/16.supplement_1.s46] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
This phase 1 trial was conducted to evaluate the safety and tolerance of didanosine (ddI) in subjects with AIDS or AIDS-related complex (ARC) who previously had demonstrated hematologic intolerance of zidovudine. Thirty subjects, 21 with AIDS and nine with ARC, were enrolled. Initially, didanosine was administered orally twice daily for a total daily dose of either 750 mg or 1,500 mg. Subsequently, the dosage for those receiving 1,500 mg/d was reduced to a maximum of 750 mg/d (375 mg twice daily) when data from this and other phase 1 studies showed that the dosage of 1,500 mg/d (750 mg twice daily) was associated with an unacceptable risk of developing neuropathy. The subjects were studied for 46 weeks (mean time; range, 7-122 weeks). The dose-limiting toxic effect observed was peripheral neuropathy, which occurred in eight patients. Other significant toxic effects included pancreatitis in three patients and xerostomia in eleven. In general, didanosine was well tolerated from a hematologic standpoint by the majority of patients during prolonged administration.
Collapse
Affiliation(s)
- J D Allan
- New England Deaconess Hospital, Division of Infectious Diseases, Boston, Massachusetts 02215
| | | | | | | | | | | | | |
Collapse
|
23
|
Schacter LP, Rozencweig M, Beltangady M, Allan JD, Canetta R, Cooley TP, Dolin R, Kelley S, Lambert J, Liebman HA. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Blood 1992; 80:2969-76. [PMID: 1467512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Myelosuppression is associated with human immunodeficiency virus (HIV) infection and may also be produced by agents used for the treatment of the disease or the treatment of its complications. Didanosine (ddl; 2',3'-dideoxyinosine) is a newer purine nucleoside that has recently become available for therapy for HIV infection. The effects of didanosine on peripheral blood counts have been retrospectively evaluated in the first 170 patients treated with this new agent in four phase I trials. Patients treated with didanosine showed statistically significant improvements in hemoglobin levels, white cell counts, and granulocyte and platelet numbers as compared with baseline values. These changes were seen with or without prior therapy with zidovudine, were somewhat more pronounced at higher doses of didanosine, and persisted for up to 1 year. Reported adverse events included peripheral neuropathy, diarrhea, and most notably, pancreatitis. It is concluded that, while some toxic side effects occur, didanosine therapy in HIV infection is associated with an amelioration of HIV-induced myelosuppression.
Collapse
Affiliation(s)
- L P Schacter
- Bristol-Myers Squibb, Wallingford, CT 06492-7690
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Kjorstad K, Harris A, Bertelsen K, Slevin M, Schultz H, Hellman K, Janssens N, Martin A, Canetta R. A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report. Ann Oncol 1992; 3:217-22. [PMID: 1586619 DOI: 10.1093/oxfordjournals.annonc.a058155] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
A phase II trial of single-agent carboplatin in advanced ovarian cancer was performed by 19 institutions from 10 European countries. A total of 260 patients were treated, with a median age of 55 (range: 20-79) years. Karnofsky performance status was 80-100 in about two-thirds of the patients. Prior therapy consisted of surgery only in 31 patients, irradiation in 9, chemotherapy without cisplatin in 45, and with cisplatin in 175. Carboplatin was administered as second-line therapy in about one-half and as third-line or more in one additional third of the study population. Initial dose was 400 mg/m2 in 90, 360 mg/m2 in 152, and 320 mg/m2 or less in 18 patients. A total of 971 courses (mean 3.7, median 2, range: 1-13) of therapy were administered. A total of 16 complete and 46 partial responses were observed in 226 evaluable patients, for an objective response rate of 27%. Efficacy was greater in chemotherapy-untreated patients (51% vs. 23%, p = 0.002). In cisplatin-pretreated patients activity was significantly higher in non-refractory patients (26% vs. 4%, p = 0.015). Myelosuppression was the most significant side effect. However, low hematologic counts seldom translated into clinically significant complications. Patients with impaired baseline creatinine clearance and poor performance status were at higher risk of developing severe myelosuppression during the initial course of treatment. Non hematologic side effects were rare and mild, except for emesis. Carboplatin has a definite role in the treatment of ovarian cancer, but almost complete cross-resistance with the parent compound was observed clinically.
Collapse
Affiliation(s)
- K Kjorstad
- Bristol-Myers Study Group Brussels, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Connolly KJ, Allan JD, Fitch H, Jackson-Pope L, McLaren C, Canetta R, Groopman JE. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am J Med 1991; 91:471-8. [PMID: 1659189 DOI: 10.1016/0002-9343(91)90182-w] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
PURPOSE To evaluate the safety and hematologic tolerance of 2'-3'-dideoxyinosine (didanosine, ddI) in subjects with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex and prior hematologic intolerance to zidovudine. PATIENTS AND METHODS A Phase I trial with two dose groups at a single-center, university-affiliated hospital ambulatory care center. Of 30 subjects enrolled, 21 had AIDS and nine had AIDS-related complex. All had CD4 lymphocyte counts less than 0.2 x 10(9)/L at entry. Didanosine was administered orally twice daily at a total daily dose of 750 mg or 1,500 mg for 12 weeks. Subjects who completed the 12-week study continued to receive ddI at the lower dose. All subjects were monitored for toxicity. Virologic and immunologic response markers were also measured. RESULTS For the group as a whole, there was no significant decrease in mean hemoglobin level or leukocyte or platelet counts. The dose-limiting toxicity was peripheral neuropathy. Other significant toxicities included pancreatitis and hypocalcemia. Uric acid elevations were common but were without clinical consequence. A sustained decrease in serum p24 antigen of at least 50% was noted in 42% of subjects who were p24 antigen-positive at entry. The mean CD4 lymphocyte count showed an initial increase that was not sustained over the 12-week study. All subjects remained anergic to skin testing. CONCLUSIONS Didanosine is well tolerated hematologically in some patients with prior significant hematologic intolerance to zidovudine. The toxicity profile for ddI differs from that of zidovudine and includes peripheral neuropathy and pancreatitis. Changes in CD4 lymphocyte number and HIV p24 antigen levels in some patients suggest antiviral activity of ddI in this population.
Collapse
Affiliation(s)
- K J Connolly
- Section of Infectious Disease, New England Deaconess Hospital, Boston, Massachusetts
| | | | | | | | | | | | | |
Collapse
|
26
|
Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L. Overview of hormonal therapy in advanced breast cancer. Semin Oncol 1990; 17:38-46. [PMID: 2148026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Hormonal therapy of breast cancer is widely used and effective. Although never curative in advanced disease, significant palliation and durable remissions can be obtained with a wide variety of hormonal manipulations. Historically, surgical ablation was used to reduce endogenous hormone levels, but this invasive procedure has been largely supplanted by drugs that reduce hormone secretion or block steroid hormone activity. A number of such antagonists are available, with tamoxifen probably the most widely used. Response can also be achieved with hormone agonists. Estrogens and androgens or their congeners have about the same level of activity as surgical ablation or drug antagonists (20% to 30% overall response rate). The progestins, another class of agonists, are also effective in the palliation of advanced breast cancer. Megestrol acetate, in part because of its oral formulation, is probably the most commonly used progestational drug for the treatment of breast cancer. Reports of 16 trials involving 1,342 patients show a response rate of 26% in patients with advanced breast cancer treated with megestrol acetate. The drug has proved active in a small number of male patients and, in randomized trials, it has been shown to be comparable with tamoxifen in efficacy (30% response for megestrol acetate v 35% for tamoxifen). Studies are currently under way to evaluate the possibility that high doses of megestrol acetate may increase response rates, and to determine whether weight gain, a well-described effect of this drug, may prove beneficial in cancer treatment.
Collapse
Affiliation(s)
- L P Schacter
- Pharmaceutical Research and Development Division, Bristol-Myers Squibb, Wallingford, CT 06492
| | | | | | | | | | | |
Collapse
|
27
|
Speyer JL, Beller U, Colombo N, Sorich J, Wernz JC, Hochster H, Green M, Porges R, Muggia FM, Canetta R. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol 1990; 8:1335-41. [PMID: 2199620 DOI: 10.1200/jco.1990.8.8.1335] [Citation(s) in RCA: 63] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cycles at a starting dose of 200 mg/m2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (greater than 60 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.
Collapse
Affiliation(s)
- J L Speyer
- Rita and Stanley H. Kaplan Cancer Center, Department of Medicine, New York University Medical Center
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Rozencweig M, McLaren C, Beltangady M, Ritter J, Canetta R, Schacter L, Kelley S, Nicaise C, Smaldone L, Dunkle L. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients. Rev Infect Dis 1990; 12 Suppl 5:S570-5. [PMID: 2166965 DOI: 10.1093/clinids/12.supplement_5.s570] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Ninety-two adult patients with AIDS or severe AIDS-related complex were treated with 2',3'-dideoxyinosine (didanosine; ddI) at dosages ranging from 0.8 to 66.0 mg/(kg.d) for at least 6 weeks in phase I trials. Potentially beneficial changes in weight (40% of patients), clinical signs or symptoms (40% of patients), CD4+ cell counts (25% of patients), and serum levels of HIV p24 antigen (50% of antigen-positive patients) were reported. Response rates tended to be higher among patients with AIDS-related complex and among those who had not received prior zidovudine therapy. A major response (improvement in at least one clinical parameter and in at least one laboratory marker) occurred in 29% of patients, and rates of major response tended to be higher in patients receiving higher dosages. The primary dose-limiting toxicity observed was peripheral neuropathy, which was observed with increasing frequency in patients receiving greater than 20 mg/(kg.d). Of the other adverse effects, pancreatitis was possibly dose-dependent and hyperuricemia (without clinical gout) occurred only at high doses. Dosages of 250 mg and 375 mg of ddI twice daily will be used in extended phase II/III studies.
Collapse
Affiliation(s)
- M Rozencweig
- Bristol-Myers Squibb Company, Pharmaceutical Research and Development Division, Wallingford, Connecticut 06492-7660
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Colombo N, Speyer JL, Green M, Canetta R, Beller U, Wernz JC, Meyers M, Widman T, Blum RH, Piccart M. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. Cancer Chemother Pharmacol 1989; 23:323-8. [PMID: 2650904 DOI: 10.1007/bf00292413] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Carboplatin (CBDCA) is a second-generation cisplatin analog that has shown activity in early clinical trials. Its spectrum of toxicity is quantitatively and qualitatively different from that of the parent compound. Between November 1984 and September 1986 we conducted a phase II trial of CBDCA in 46 women with epithelial ovarian cancer. All patients had undergone at least one prior chemotherapy regimen; 41 (89%) had previously received cisplatin (mean cumulative dose, 540 mg/m2). The CBDCA dose was based on renal function and was injected i.v. once every 4 weeks. Patients were stratified on the basis of baseline creatinine clearance: those with a baseline creatinine clearance of greater than or equal to 60 ml/min received 400 mg/m2 CBDCA; those with a creatinine clearance between 30 and 60 ml/min received an initial dose calculated according to a previously published formula that corrected for renal insufficiency and projected nadir platelet counts of 75,000/mm3. Of 41 evaluable patients, 6 (15%) had an objective response [2 complete responses (CRs); 4 partial responses (PRs)]; 5 of the 6 responders had previously responded to cisplatin treatment. No responses were observed in 12 patients who had not responded to prior cisplatin therapy. Significant hematologic toxicity was seen. Of 18 patients with a creatinine clearance of greater than or equal to 60 ml/min (dose, 400 mg/m2), 6 had nadir platelet counts of less than 25,000/mm3, 4 with symptomatic bleeding. Of the 21 evaluable patients for whom the dose-modification formula was applied, 10 had nadir platelet counts of less than 75,000/mm3; 5 had counts of less than 50,000/mm3. CBDCA has activity even in patients who have previously undergone extensive cisplatin therapy; however, its toxicity is variable and thrombocytopenia is dose-limiting. We did not confirm the ability of the above-mentioned formula to calculate the CBDCA dose and accurately predict the nadir platelet count for all patients. Other factors, such as prior radiotherapy, may also be important in the dosing of CBDCA in pretreated patients.
Collapse
Affiliation(s)
- N Colombo
- Division of Oncology, New York University Medical Center, NY 10016
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- L Schacter
- Pharmaceutical Research and Development Division, Bristol-Myers Co., Wallingford, CT 06492
| | | | | | | | | | | |
Collapse
|
31
|
Affiliation(s)
- R Canetta
- Bristol-Myers Company, Pharmaceutical Research and Development, Wallingford, CT 06492-7600
| | | | | | | |
Collapse
|
32
|
Canetta R, Franks C, Smaldone L, Bragman K, Rozencweig M. Clinical status of carboplatin. Oncology (Williston Park) 1987; 1:61-70. [PMID: 3079484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Carboplatin, a cisplatin derivative, shows promise of being an effective weapon against ovarian, cervical, and small-cell lung cancer, as well as epidermoid cancer of the head and neck, with fewer toxic effects than cisplatin. It has successfully completed phase III investigation and clinical trials continue.
Collapse
Affiliation(s)
- R Canetta
- Bristol-Myers Company, Pharmaceutical Research and Development Division, Wallingford, Connecticut
| | | | | | | | | |
Collapse
|
33
|
Tirelli U, Carbone A, Zagonel V, Veronesi A, Canetta R. Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol 1987; 23:535-40. [PMID: 3653177 DOI: 10.1016/0277-5379(87)90316-6] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The results of 2 consecutive and prospective trials with specifically devised chemotherapy regimens in elderly patients (pts) with non-Hodgkin's lymphoma (NHL) are reported. Between August 1979 and September 1984, 66 pts aged 70 or older (median 75 years) with NHL entered 2 consecutive trials, the former with single agent teniposide 100 mg/m2 i.v. weekly (41 pts), the latter with etoposide and prednimustine (E + P), 100 mg/m p.o. for 5 days every 21 days (25 pts). Forty-five pts were previously untreated, 21 previously treated. Forty-seven pts were of the intermediate and high grade groups according to the Working Formulation; 19 pts were of the low grade; 57 pts were stages III and IV, 9 pts were stages I and II. The median performance status was 70 (range 30-100). The objective response rate in the 66 evaluable pts is 53% with 38% CR; the 3-year overall, disease-free and CR survivals are 21, 12 and 40% respectively. The objective response rate in the 45 previously untreated pts is 58% with 42% CR; the 3-year overall, disease-free and CR survivals are 24, 16 and 58% respectively. The overall toxicity was mild. Severe toxicity (grade III and IV according to WHO criteria) was observed only in 16/498 courses (3.2%), with 1 toxic death (grade IV leucopenia). We experienced the usefulness of a properly orientated clinical approach to elderly pts with NHL. We suggest that a combination regimen like E + P, suitable for oral administration, may be safely employed in a large fraction of pts with NHL.
Collapse
Affiliation(s)
- U Tirelli
- Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy
| | | | | | | | | |
Collapse
|
34
|
Abstract
The existing literature data base on carboplatin updated to June, 1985 has been reviewed. The compound seems to retain the same spectrum of activity as cisplatin, and a definite set of efficacy data is available for ovarian cancer of epithelial origin, small cell carcinoma of the lung and epidermoid carcinoma of the head and neck. A yet unpublished toxicity data base on carboplatin suggests that the compound has an improved therapeutic index over the parent compound, cisplatin, and that it does not seem inferior to another platinum coordination compound currently in clinical trials, iproplatin.
Collapse
|
35
|
|
36
|
|
37
|
Tirelli U, D'Incalci M, Canetta R, Tumolo S, Franchin G, Veronesi A, Galligioni E, Trovò MG, Rossi C, Grigoletto E. Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol 1984; 2:432-7. [PMID: 6726296 DOI: 10.1200/jco.1984.2.5.432] [Citation(s) in RCA: 68] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Twenty-two consecutive patients with recurrent malignant brain tumors after radiation therapy and systemic combination chemotherapy with BCNU and vincristine, four of whom were not evaluable due to early death, were treated with etoposide (VP-16-213) (50-100 mg/m2 for five days every three weeks). Response, defined as improvement in both clinical examination and computed tomography scan in absence of glucocorticoids dosage increase, was observed in three (17%) of 18 evaluable patients, lasting greater than 21, seven, and two months, respectively. Six additional patients had stable disease for greater than 10, seven, four, four, three, and two months: all of them had improvement of clinical symptoms but no variation in their scans. Overall median survival from the start of VP-16-213 was 4.5 months (range, 1-23 + months), whereas patients with response or stable disease had a median survival of eight months. Overall, treatment was well tolerated. In 10 patients concomitant plasma and cerebrospinal fluid samples were evaluated with a high-performance liquid chromatographic method for drug assay. The concentration of VP-16-213 in cerebrospinal fluid was less than 1% that found in plasma, even in the two patients with response. The activity of etoposide in patients with malignant, lomustine-vincristine-resistant brain tumors suggests an interesting potential use for this drug.
Collapse
|
38
|
Monfardini S, Rilke F, Valagussa P, Bajetta E, Canetta R, Buzzoni R, Giardini R, Viviani S. A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. Eur J Cancer Clin Oncol 1984; 20:609-17. [PMID: 6203753 DOI: 10.1016/0277-5379(84)90005-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
One-hundred and ninety-four adult patients with histologically proven stage III and IV non-Hodgkin's lymphomas, treated with CVP (cyclophosphamide, vincristine and prednisone) alternated with ABP (adriamycin, bleomycin and prednisone), were analyzed to test the validity of the clinicoprognostic correlation offered by the working formulation in comparison with the Rappaport and Kiel classifications. Actuarial overall survival at 5 yr showed a significant difference among the three prognostic subgroups of the working formulation (low grade, 53.3%; intermediate grade, 47.5%; high grade, 27.7%). Overall survival of favorable subgroups of the Rappaport and Kiel classifications was superior to that of unfavorable prognostic groups. The percentage of systemic symptoms and bulky disease increased in patients with low-grade compared to those with intermediate-grade and intermediate-to-high-grade malignancy. The achievement of complete remission was not related to any of the prognostic groups of the Working Formulation, and no difference could be detected within the various prognostic groups of the Rappaport and Kiel classifications. Within the diffuse histiocytic lymphomas of the Rappaport classification, two groups with a different prognostic outcome were evidenced by the working formulation (G, with an overall survival of 50%, and H, with an overall survival of 26.7% at 5 yr) and by the Kiel classification. The possibility of reporting results in the three different groups of the working formulation instead of two can be considered a step forward. Within the diffuse histiocytic histology, the working formulation allows separation, as does the Kiel classification, into two main different prognostic subgroups.
Collapse
|
39
|
|
40
|
|
41
|
Abstract
The unique biological properties and therapeutic efficacy of the podophyllotoxin derivatives, Vumon (VM26, teniposide) and Vepesid (VP16-213, etoposide), are stimulating the interest of both laboratory and clinical researchers. Investigations on new pharmaceutical formulations, pharmacokinetics and metabolism are providing more appropriate information in drug administration; experimental chemotherapy indicates that, among others, cytosine arabinoside and cisplatin are highly synergistic with podophyllotoxins; single agent and combination treatment clinical trials are defining the respective role of Vumon and Vepesid in cancer chemotherapy.
Collapse
|
42
|
Sanfilippo O, Daidone MG, Costa A, Canetta R, Silvestrini R. Estimation of differential in vitro sensitivity of non-Hodgkin lymphomas to anticancer drugs. Eur J Cancer 1981; 17:217-26. [PMID: 6167446 DOI: 10.1016/0014-2964(81)90039-6] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
43
|
Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E, Gallagher CG, von Melchner H, Hayat M, Ribaud P, De Wasch G, Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, Ten Bokkel-Huyninck W, Perevodchikova NI, Manziuk LA, Senn HJ, Mayr AC. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63:827-34. [PMID: 455324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Valuable information was collected on the medical history and clinical course of 1273 patients entered in clinical trials with Adriamycin (ADR) carried out in 12 European cancer centers. A coded patient form was used for the data collection carried out in each center by a qualified physician following a guideline which was discussed and accepted by all of the participants. The aim of the study was to define the incidence, characteristics, and possible co-factors of the cardiomyopathy (CMP) in patients treated with combination chemotherapy regimens including ADR. The mean total dose of ADR was 268 mg/m2 (range, 15--1251 mg/m2), and 5.1% of the patients received a total dose of greater than 550 mg/m2. A "definite" ADR-related CMP was observed in 1.7% of the cases; another 3% of the cases were reported as "possible" ADR-CMP since the role played by the drug could not be clearly defined. "Definite" ADR-CMP was fatal in eight patients (0.6%) while "possible" ADR-CMP was fatal in 13 patients (1.0%). Among the possible co-factors examined, the following ones were found to be significantly associated with the occurrence of a "definite" ADR-CMP: (a) total dose of ADR; (b) vincristine when given both before and concomitantly with ADR; (c) bleomycin when given before ADR; and (d) radiotherapy to the mediastinum when given concomitantly with ADR. Furthermore, none of 182 patients receiving ADR by slow infusion developed a "definite" ADR-CMP, while 2% of the patients treated by bolus injection did so. The occurrence of a "possible" ADR-CMP was found to be significantly associated with two pre-existing pathologic conditions (electrocardiogram [ECG] abnormalities and hypertension) but not with the treatment-related co-factors for the "definite" ADR-CMP mentioned above. Other variables examined, such as sex, age, cancer type, baseline liver function, and cyclophosphamide treatment, did not seem to influence the risk of ADR-CMP. Data on ECG changes occurring during ADR treatment were also reported and their incidence was found to be strictly related to the frequency of the ECG monitoring.
Collapse
|
44
|
Canetta R. [Not Available]. Econ Stor 1978; 25:52-64. [PMID: 11631950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
45
|
Abstract
120 adults were given a task to determine whether performance on an oral perception task declines with increasing chronological age. Subjects in their 70's performed significantly worse than those in their 60's and younger. This loss of oral perceptual skills is considered relevant to the remediation and training of older individuals with difficulties in speech articulation.
Collapse
|
46
|
Beretta G, Spinelli P, Rilke F, Tancini G, Canetta R, Gennari L, Bonadonna G. Sequential laparoscopy and laparotomy combined with bone marrow biopsy in staging Hodgkin's disease. Cancer Treat Rep 1976; 60:1231-7. [PMID: 138479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
In a series of 121 unselected, previously untreated patients with Hodgkin's disease staging laparoscopy combined with needle bone marrow biopsy detected the presence of extranodal disease in the liver or marrow or both in 9% of the patients. A spleen biopsy yielded positive findings in 13%. Subsequent laparotomy with open marrow biopsy performed in 110 patients with negative liver and marrow findings from the first combined procedure revealed the presence of extranodal hepatic lymphoma in two additional spleens. Surgical marrow biopsy was always interpretey. Although devoid of major complications, biopsy of the spleen is not recommended as a routine procedure in staging laparoscopy. This prospective sequential study confirms that laparoscopy plus needle marrow biopsy is a useful, rapid, safe, and economic procedure to establish stage IV disease in the large majority of patients with nodal involvement. Considering the recent more extensive use of chemotherapy for intermediate stages of Hodgkin's disease, our findings suggest that laparotomy with splenectomy needs a critical re-evaluation as a routine staging procedure for patients with no overt extranodal lymphoma.
Collapse
|